13F Holdings
中文EN

PLSE PULSE BIOSCIENCES, INC.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1625101 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,637.2%
TTM net income YoY-12.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin26.8%
Operating margin-5,821.1%
Net margin-5,603.9%
FCF margin-4,263.9%
EBITDA margin-5,796.8%

Returns

ROE-60.6%
ROA-54.0%
ROIC (approx.)-95.2%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets8.9%
Debt / equity0.00x
Current ratio14.35x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-13.1%
Payout ratio—
Capex / revenue24.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$350,000$0$0$700,000$1.42M
Cost of revenue$539,000$0$0$11.94M$1.97M
Gross profit-$189,000$0$0-$11.24M-$550,000
R&D expense$44.72M$32.34M$27.80M$20.84M$28.64M
SG&A expense$32.03M$23.92M$15.78M$13.96M$19.07M
Operating income-$76.94M-$56.26M-$43.57M-$58.06M-$63.01M
Pretax income$72.80M$53.60M-$42.21M-$58.51M-$63.66M
Income tax$0$0$0$0$0
Net income-$72.78M-$53.59M-$42.21M-$58.51M-$63.66M
EBITDA-$76.53M-$55.74M-$43.03M-$57.37M-$62.53M
EPS (basic)-1.08-0.92-0.85-1.72-2.28
EPS (diluted)————-2.28
Weighted avg. shares (diluted)————27.96M
Balance sheet
Cash & equivalents$80.73M$118.04M$44.37M$61.14M$44.37M
Receivables$274,000$0—$0$61,000
Inventory$136,000$0—$0$5.82M
Current assets$83.42M$119.45M$45.33M$62.15M$45.33M
PP&E, net$1.05M$1.16M$1.53M$1.96M$1.53M
Goodwill$2.79M$2.79M$2.79M$2.79M$2.79M
Intangibles$575,000$1.22M$1.89M$2.55M$1.89M
Total assets$94.54M$132.46M$59.15M$77.88M$59.15M
Current liabilities$7.92M$10.05M$6.71M$5.98M$6.71M
Total liabilities$13.88M$17.60M$14.79M$80.12M$14.79M
Shareholders' equity$80.66M$114.86M$44.36M-$2.25M$44.36M
Shares outstanding67.84M65.93M55.14M37.23M55.14M
Cash flow statement
Operating cash flow-$54.12M-$36.34M-$33.04M-$47.01M-$54.10M
Capital expenditure$315,000$125,000$121,000$401,000$437,000
Free cash flow-$54.44M-$36.47M-$33.16M-$47.41M-$54.53M
Investing cash flow-$335,000-$125,000-$121,000-$401,000$7.56M
Financing cash flow$17.15M$110.14M$16.39M$79.94M$62.69M
Depreciation & amortization$406,000$512,000$542,000$690,000$480,000
Stock-based compensation$21.46M$13.59M$7.18M$5.19M$14.60M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.